Literature DB >> 17627496

Minocycline and cytoprotection: shedding new light on a shadowy controversy.

J Jordan1, F J Fernandez-Gomez, M Ramos, I Ikuta, N Aguirre, M F Galindo.   

Abstract

In this review we explore and integrate the knowledge of the plausible pharmacological targets that could explain the new application for the well known semi-synthetic, tetracycline-derivate minocycline as a cytoprotective drug. In doing so, we will analyze the possible mechanisms to elucidate the potential cytoprotective properties of minocycline. We address its anti-oxidant action ranging from its structure to its capacity to modulate the expression of oxidant-related enzymes such as nitric oxide synthase. The pharmacological targets responsible for its anti-inflammatory effects are surveyed. The effects of this antibiotic are making its marks on intracellular pathways related to neurodegenerative processes such as mitochondrially-mediated apoptosis, including minocycline-modulated effects on the expression of apoptotic proteins. Finally, we will explore the effects of minocycline on metalloproteinases, enzymes implicated in the modulation of cerebrovascular post-ischemic oxidative reperfusion injury, and new targets. In conclusion, we shed new light on the shadowy controversy of minocycline's potential cytoprotective mechanisms and targets of action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627496     DOI: 10.2174/156720107781023938

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  23 in total

1.  Minocycline recovers MTT-formazan exocytosis impaired by amyloid beta peptide.

Authors:  Peter Kreutzmann; Gerald Wolf; Kathleen Kupsch
Journal:  Cell Mol Neurobiol       Date:  2010-05-09       Impact factor: 5.046

2.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

3.  Metal ion-assisted self-assembly of complexes for controlled and sustained release of minocycline for biomedical applications.

Authors:  Zhiling Zhang; Zhicheng Wang; Jia Nong; Camilla A Nix; Hai-Feng Ji; Yinghui Zhong
Journal:  Biofabrication       Date:  2015-01-20       Impact factor: 9.954

4.  Mesenchymal Stromal/Stem Cell and Minocycline-Loaded Hydrogels Inhibit the Growth of Staphylococcus aureus that Evades Immunomodulation of Blood-Derived Leukocytes.

Authors:  Alberto Daniel Guerra; David Antonio Cantu; Joseph T Vecchi; Warren E Rose; Peiman Hematti; Weiyuan John Kao
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

Review 5.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection.

Authors:  Diego Romero-Perez; Eduardo Fricovsky; Katrina Go Yamasaki; Michael Griffin; Maraliz Barraza-Hidalgo; Wolfgang Dillmann; Francisco Villarreal
Journal:  J Am Coll Cardiol       Date:  2008-09-23       Impact factor: 24.094

Review 7.  Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation.

Authors:  Raimondo D'Ambrosio; Clifford L Eastman; Cinzia Fattore; Emilio Perucca
Journal:  Expert Rev Neurother       Date:  2013-06       Impact factor: 4.618

8.  Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus.

Authors:  Vinicia Campana Biancardi; Alexis M Stranahan; Eric G Krause; Annette D de Kloet; Javier E Stern
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-12-04       Impact factor: 4.733

9.  Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase.

Authors:  Amarjit S Naura; Hogyoung Kim; Jihang Ju; Paulo C Rodriguez; Joaquin Jordan; Andrew D Catling; Bashir M Rezk; Zakaria Y Abd Elmageed; Kusma Pyakurel; Abdelmetalab F Tarhuni; Mohammad Q Abughazleh; Youssef Errami; Mourad Zerfaoui; Augusto C Ochoa; A Hamid Boulares
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

Review 10.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.